首页> 外文期刊>Pharmacological reviews >International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.
【24h】

International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors.

机译:国际药理学联合会。二十五。腺苷受体的命名和分类。

获取原文
获取原文并翻译 | 示例
           

摘要

Four adenosine receptors have been cloned and characterized from several mammalian species. The receptors are named adenosine A(1), A(2A), A(2B), and A(3). The A(2A) and A(2B) receptors preferably interact with members of the G(s) family of G proteins and the A(1) and A(3) receptors with G(i/o) proteins. However, other G protein interactions have also been described. Adenosine is the preferred endogenous agonist at all these receptors, but inosine can also activate the A(3) receptor. The levels of adenosine seen under basal conditions are sufficient to cause some activation of all the receptors, at least where they are abundantly expressed. Adenosine levels during, e.g., ischemia can activate all receptors even when expressed in low abundance. Accordingly, experiments with receptor antagonists and mice with targeted disruption of adenosine A(1), A(2A), and A(3) expression reveal roles for these receptors under physiological and particularly pathophysiological conditions. There are pharmacological tools that can be used to classify A(1), A(2A), and A(3) receptors but few drugs that interact selectively with A(2B) receptors. Testable models of the interaction of these drugs with their receptors have been generated by site-directed mutagenesis and homology-based modelling. Both agonists and antagonists are being developed as potential drugs.
机译:已从几种哺乳动物物种中克隆并表征了四种腺苷受体。受体被命名为腺苷A(1),A(2A),A(2B)和A(3)。 A(2A)和A(2B)受体优选与G蛋白的G(s)家族成员以及具有G(i / o)蛋白的A(1)和A(3)受体相互作用。然而,也已经描述了其他G蛋白相互作用。腺苷是所有这些受体的首选内源性激动剂,但肌苷也可以激活A(3)受体。在基础条件下观察到的腺苷水平足以引起所有受体的某种活化,至少在它们充分表达的地方。即使缺血时腺苷水平低表达也能激活所有受体。因此,用受体拮抗剂和靶向破坏腺苷A(1),A(2A)和A(3)表达的小鼠进行的实验揭示了这些受体在生理尤其是病理生理条件下的作用。有一些药理学工具可用于对A(1),A(2A)和A(3)受体进行分类,但很少有与A(2B)受体选择性相互作用的药物。通过定点诱变和基于同源性的建模已生成了这些药物与其受体相互作用的可测试模型。激动剂和拮抗剂都被开发为潜在药物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号